Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives
The standard treatment for locally advanced gastric cancer differs across the world. In western countries, perioperative chemotherapy or postoperative adjuvant chemoradiotherapy are the preferred treatment options, whereas in Asia, D2 gastrectomy followed by postoperative adjuvant chemotherapy is st...
Gespeichert in:
| Veröffentlicht in: | Surgery today (Tokyo, Japan) Japan), 2020-01, Vol.50 (1), p.30-37 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | 1 |
| container_start_page | 30 |
| container_title | Surgery today (Tokyo, Japan) |
| container_volume | 50 |
| creator | Tokunaga, Masanori Sato, Yuya Nakagawa, Masatoshi Aburatani, Tomoki Matsuyama, Takatoshi Nakajima, Yasuaki Kinugasa, Yusuke |
| description | The standard treatment for locally advanced gastric cancer differs across the world. In western countries, perioperative chemotherapy or postoperative adjuvant chemoradiotherapy are the preferred treatment options, whereas in Asia, D2 gastrectomy followed by postoperative adjuvant chemotherapy is standard. In Japan, adjuvant chemotherapy with S-1 is the standard treatment for pStage II gastric cancer, whereas adjuvant chemotherapy with a doublet regimen is preferred for pStage III gastric cancer. The efficacy of preoperative neoadjuvant chemotherapy using S-1 plus cisplatin, has been investigated in selected patients with expected poor survival outcomes. To expand the indications for neoadjuvant chemotherapy, a clinical trial investigating the efficacy of preoperative S-1 plus oxaliplatin in patients with cStage III (cT3-4N1-3) gastric cancer (JCOG1509) is ongoing in Japan. The addition of immune checkpoint inhibitors to cytotoxic chemotherapy also seems promising and is being investigated in international randomized clinical trials. Although we have to await the final results of these studies, preoperative neoadjuvant chemotherapy is a promising treatment strategy and likely to become standard treatment for locally advanced gastric cancer in Japan. |
| doi_str_mv | 10.1007/s00595-019-01896-5 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6954129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31612329</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-f19d9114202f6914ae7adf423c37ae09b68b621e64ec4ad0e0360c58c7a50c1d3</originalsourceid><addsrcrecordid>eNp9kMFq3DAQhkVpaLZpXyCHoBdwOyPJWquHQglpkhJIDslZzMrjXQevbSR7Yd--2mwb2ksOwzDM_J_EJ8Q5whcEWH5NAKUrC0CXq3K2KN-JBRptC1Whfi8W4AwWqByeio8pPQMoUwF8EKcaLSqt3EJsHji2w8iRpnbHMmx4O0ybPI572QxRdkOgrttLqnfUB67lmtIU2yDDYYyy7eUvGqn_JsMcI_eTpL6WzTzNkWXGppHDgZw-iZOGusSf__Qz8fTz6vHypri7v769_HFXhFLbqWjQ1Q7RKFCNdWiIl1Q3Rumgl8TgVrZaWYVsDQdDNTBoC6GswpJKCFjrM_H9yB3n1ZbrkL8UqfNjbLcU936g1v-_6duNXw87b11psqsMUEdAiENKkZvXLII_ePdH7z579y_efZlDF_---hr5Kzof6ONByqt-zdE_D3Pss4m3sL8Bk_-Rvg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Tokunaga, Masanori ; Sato, Yuya ; Nakagawa, Masatoshi ; Aburatani, Tomoki ; Matsuyama, Takatoshi ; Nakajima, Yasuaki ; Kinugasa, Yusuke</creator><creatorcontrib>Tokunaga, Masanori ; Sato, Yuya ; Nakagawa, Masatoshi ; Aburatani, Tomoki ; Matsuyama, Takatoshi ; Nakajima, Yasuaki ; Kinugasa, Yusuke</creatorcontrib><description>The standard treatment for locally advanced gastric cancer differs across the world. In western countries, perioperative chemotherapy or postoperative adjuvant chemoradiotherapy are the preferred treatment options, whereas in Asia, D2 gastrectomy followed by postoperative adjuvant chemotherapy is standard. In Japan, adjuvant chemotherapy with S-1 is the standard treatment for pStage II gastric cancer, whereas adjuvant chemotherapy with a doublet regimen is preferred for pStage III gastric cancer. The efficacy of preoperative neoadjuvant chemotherapy using S-1 plus cisplatin, has been investigated in selected patients with expected poor survival outcomes. To expand the indications for neoadjuvant chemotherapy, a clinical trial investigating the efficacy of preoperative S-1 plus oxaliplatin in patients with cStage III (cT3-4N1-3) gastric cancer (JCOG1509) is ongoing in Japan. The addition of immune checkpoint inhibitors to cytotoxic chemotherapy also seems promising and is being investigated in international randomized clinical trials. Although we have to await the final results of these studies, preoperative neoadjuvant chemotherapy is a promising treatment strategy and likely to become standard treatment for locally advanced gastric cancer in Japan.</description><identifier>ISSN: 0941-1291</identifier><identifier>EISSN: 1436-2813</identifier><identifier>DOI: 10.1007/s00595-019-01896-5</identifier><identifier>PMID: 31612329</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy, Adjuvant - trends ; Drug Combinations ; Gastrectomy - methods ; Humans ; Japan ; Medicine ; Medicine & Public Health ; Neoadjuvant Therapy - trends ; Neoplasm Staging ; Oxaliplatin - administration & dosage ; Oxonic Acid - administration & dosage ; Preoperative Care - trends ; Review ; Review Article ; Stomach Neoplasms - pathology ; Stomach Neoplasms - surgery ; Surgery ; Surgical Oncology ; Tegafur - administration & dosage</subject><ispartof>Surgery today (Tokyo, Japan), 2020-01, Vol.50 (1), p.30-37</ispartof><rights>The Author(s) 2019. corrected publication 2020</rights><rights>The Author(s) 2019, corrected publication 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-f19d9114202f6914ae7adf423c37ae09b68b621e64ec4ad0e0360c58c7a50c1d3</citedby><cites>FETCH-LOGICAL-c536t-f19d9114202f6914ae7adf423c37ae09b68b621e64ec4ad0e0360c58c7a50c1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00595-019-01896-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00595-019-01896-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31612329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tokunaga, Masanori</creatorcontrib><creatorcontrib>Sato, Yuya</creatorcontrib><creatorcontrib>Nakagawa, Masatoshi</creatorcontrib><creatorcontrib>Aburatani, Tomoki</creatorcontrib><creatorcontrib>Matsuyama, Takatoshi</creatorcontrib><creatorcontrib>Nakajima, Yasuaki</creatorcontrib><creatorcontrib>Kinugasa, Yusuke</creatorcontrib><title>Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives</title><title>Surgery today (Tokyo, Japan)</title><addtitle>Surg Today</addtitle><addtitle>Surg Today</addtitle><description>The standard treatment for locally advanced gastric cancer differs across the world. In western countries, perioperative chemotherapy or postoperative adjuvant chemoradiotherapy are the preferred treatment options, whereas in Asia, D2 gastrectomy followed by postoperative adjuvant chemotherapy is standard. In Japan, adjuvant chemotherapy with S-1 is the standard treatment for pStage II gastric cancer, whereas adjuvant chemotherapy with a doublet regimen is preferred for pStage III gastric cancer. The efficacy of preoperative neoadjuvant chemotherapy using S-1 plus cisplatin, has been investigated in selected patients with expected poor survival outcomes. To expand the indications for neoadjuvant chemotherapy, a clinical trial investigating the efficacy of preoperative S-1 plus oxaliplatin in patients with cStage III (cT3-4N1-3) gastric cancer (JCOG1509) is ongoing in Japan. The addition of immune checkpoint inhibitors to cytotoxic chemotherapy also seems promising and is being investigated in international randomized clinical trials. Although we have to await the final results of these studies, preoperative neoadjuvant chemotherapy is a promising treatment strategy and likely to become standard treatment for locally advanced gastric cancer in Japan.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemotherapy, Adjuvant - trends</subject><subject>Drug Combinations</subject><subject>Gastrectomy - methods</subject><subject>Humans</subject><subject>Japan</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoadjuvant Therapy - trends</subject><subject>Neoplasm Staging</subject><subject>Oxaliplatin - administration & dosage</subject><subject>Oxonic Acid - administration & dosage</subject><subject>Preoperative Care - trends</subject><subject>Review</subject><subject>Review Article</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - surgery</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Tegafur - administration & dosage</subject><issn>0941-1291</issn><issn>1436-2813</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kMFq3DAQhkVpaLZpXyCHoBdwOyPJWquHQglpkhJIDslZzMrjXQevbSR7Yd--2mwb2ksOwzDM_J_EJ8Q5whcEWH5NAKUrC0CXq3K2KN-JBRptC1Whfi8W4AwWqByeio8pPQMoUwF8EKcaLSqt3EJsHji2w8iRpnbHMmx4O0ybPI572QxRdkOgrttLqnfUB67lmtIU2yDDYYyy7eUvGqn_JsMcI_eTpL6WzTzNkWXGppHDgZw-iZOGusSf__Qz8fTz6vHypri7v769_HFXhFLbqWjQ1Q7RKFCNdWiIl1Q3Rumgl8TgVrZaWYVsDQdDNTBoC6GswpJKCFjrM_H9yB3n1ZbrkL8UqfNjbLcU936g1v-_6duNXw87b11psqsMUEdAiENKkZvXLII_ePdH7z579y_efZlDF_---hr5Kzof6ONByqt-zdE_D3Pss4m3sL8Bk_-Rvg</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Tokunaga, Masanori</creator><creator>Sato, Yuya</creator><creator>Nakagawa, Masatoshi</creator><creator>Aburatani, Tomoki</creator><creator>Matsuyama, Takatoshi</creator><creator>Nakajima, Yasuaki</creator><creator>Kinugasa, Yusuke</creator><general>Springer Singapore</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives</title><author>Tokunaga, Masanori ; Sato, Yuya ; Nakagawa, Masatoshi ; Aburatani, Tomoki ; Matsuyama, Takatoshi ; Nakajima, Yasuaki ; Kinugasa, Yusuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-f19d9114202f6914ae7adf423c37ae09b68b621e64ec4ad0e0360c58c7a50c1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemotherapy, Adjuvant - trends</topic><topic>Drug Combinations</topic><topic>Gastrectomy - methods</topic><topic>Humans</topic><topic>Japan</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoadjuvant Therapy - trends</topic><topic>Neoplasm Staging</topic><topic>Oxaliplatin - administration & dosage</topic><topic>Oxonic Acid - administration & dosage</topic><topic>Preoperative Care - trends</topic><topic>Review</topic><topic>Review Article</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - surgery</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Tegafur - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tokunaga, Masanori</creatorcontrib><creatorcontrib>Sato, Yuya</creatorcontrib><creatorcontrib>Nakagawa, Masatoshi</creatorcontrib><creatorcontrib>Aburatani, Tomoki</creatorcontrib><creatorcontrib>Matsuyama, Takatoshi</creatorcontrib><creatorcontrib>Nakajima, Yasuaki</creatorcontrib><creatorcontrib>Kinugasa, Yusuke</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Surgery today (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tokunaga, Masanori</au><au>Sato, Yuya</au><au>Nakagawa, Masatoshi</au><au>Aburatani, Tomoki</au><au>Matsuyama, Takatoshi</au><au>Nakajima, Yasuaki</au><au>Kinugasa, Yusuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives</atitle><jtitle>Surgery today (Tokyo, Japan)</jtitle><stitle>Surg Today</stitle><addtitle>Surg Today</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>50</volume><issue>1</issue><spage>30</spage><epage>37</epage><pages>30-37</pages><issn>0941-1291</issn><eissn>1436-2813</eissn><abstract>The standard treatment for locally advanced gastric cancer differs across the world. In western countries, perioperative chemotherapy or postoperative adjuvant chemoradiotherapy are the preferred treatment options, whereas in Asia, D2 gastrectomy followed by postoperative adjuvant chemotherapy is standard. In Japan, adjuvant chemotherapy with S-1 is the standard treatment for pStage II gastric cancer, whereas adjuvant chemotherapy with a doublet regimen is preferred for pStage III gastric cancer. The efficacy of preoperative neoadjuvant chemotherapy using S-1 plus cisplatin, has been investigated in selected patients with expected poor survival outcomes. To expand the indications for neoadjuvant chemotherapy, a clinical trial investigating the efficacy of preoperative S-1 plus oxaliplatin in patients with cStage III (cT3-4N1-3) gastric cancer (JCOG1509) is ongoing in Japan. The addition of immune checkpoint inhibitors to cytotoxic chemotherapy also seems promising and is being investigated in international randomized clinical trials. Although we have to await the final results of these studies, preoperative neoadjuvant chemotherapy is a promising treatment strategy and likely to become standard treatment for locally advanced gastric cancer in Japan.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31612329</pmid><doi>10.1007/s00595-019-01896-5</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-1291 |
| ispartof | Surgery today (Tokyo, Japan), 2020-01, Vol.50 (1), p.30-37 |
| issn | 0941-1291 1436-2813 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6954129 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy, Adjuvant - trends Drug Combinations Gastrectomy - methods Humans Japan Medicine Medicine & Public Health Neoadjuvant Therapy - trends Neoplasm Staging Oxaliplatin - administration & dosage Oxonic Acid - administration & dosage Preoperative Care - trends Review Review Article Stomach Neoplasms - pathology Stomach Neoplasms - surgery Surgery Surgical Oncology Tegafur - administration & dosage |
| title | Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T10%3A11%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perioperative%20chemotherapy%20for%20locally%20advanced%20gastric%20cancer%20in%20Japan:%20current%20and%20future%20perspectives&rft.jtitle=Surgery%20today%20(Tokyo,%20Japan)&rft.au=Tokunaga,%20Masanori&rft.date=2020-01-01&rft.volume=50&rft.issue=1&rft.spage=30&rft.epage=37&rft.pages=30-37&rft.issn=0941-1291&rft.eissn=1436-2813&rft_id=info:doi/10.1007/s00595-019-01896-5&rft_dat=%3Cpubmed_cross%3E31612329%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31612329&rfr_iscdi=true |